Stock Events

Nkarta 

$9.54
37
-$0.78-7.56% Today

Statistics

Day High
-
Day Low
-
52W High
12.2
52W Low
1.28
Volume
476,183
Avg. Volume
897,296
Mkt Cap
468.15M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MarExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-0.73
-0.28
0.18
0.63
Expected EPS
-0.55
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NKTX. It's not an investment recommendation.

Analyst Ratings

14.75$Average Price Target
The highest estimate is $22.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Show more...
CEO
Employees
127
Country
US
ISIN
US65487U1088

Listings